FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like The Best Time to Apply for a Job January 10, 2018 Zoetis To Host Webcast And Conference Call On Second Quarter 2017 Financial Results June 29, 2017 What Biogen Wants in Return for Financial Assistance of Its $750,000 a Year Drug June 11, 2017
